Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
SYSTEMIC HYPERTHERMIA IN THE TREATMENT OF HIV-RELATED MALIGNANCY: A PHASE I STUDY (MEETING ABSTRACT)
Proc Annu Meet Am Soc Clin Oncol; 11:A8 1992. Unique Identifier : AIDSLINE ICDB/92680739 Alonso K; Pontiggia P; DeBartolomei E; Calvi G; Cuppone Curto F; Nardi C; Lab. Atlanta, 203B Medical Way, Riverdale, GA 30274
Abstract:
Treatment of HIV-related malignancies with pharmacologic and biologic agents has not appreciably modified the course of disease. Immunologic impairment remains the critical factor in response. Recently, we reported the relative efficacy of total body hyperthermia on tumor response and the resulting change in clinical and laboratory parameters (Biomedicine, 1992). Now, we report the medium-term results on 27 men with substantial immunologic impairment and HIV-associated malignancies who were treated with systemic hyperthermia alone. Core temperature was raised to 42 C and held for 1 hr with extracorporeal perfusion and ex vivo blood heating as the means of temperature control. All patients (pts) were removed from antiretrovirals 72 hr before the single treatment and remained off during follow-up. Flow rates were 3-400 mL/min. Two pts died of complications secondary to treatment (cardiac arrhythmia; CNS bleed). Pressure point skin damage may occur despite adequate cushioning. 52% of pts manifest tumor regression (1 CR, 13 PR) persisting longer than 90 days. Responders showed little change in total CD4 counts if presenting total CD4 counts were below 50. Marked, sustained rises were seen in those few pts with initial CD4 counts above 200. In all responders surrogate markers reflecting HIV activity declined. In no pt was HIV activity stimulated with heat exposure. CMV retinitis did clear in some pts. EBV parameters were markedly altered with heat exposure in some pts. There is utility in the use of systemic hyperthermia to control HIV-related malignancy. Further study of agents potentiated by heat is indicated.
Keywords: Antigens, CD4/ANALYSIS Body Temperature Drug Evaluation Human Hyperthermia, Induced/*ADVERSE EFFECTS HIV Infections/*COMPLICATIONS/IMMUNOLOGY Male Neoplasms/*ETIOLOGY/IMMUNOLOGY/*THERAPY Skin/PATHOLOGY T-Lymphocyte Subsets/IMMUNOLOGY ABSTRACT CLINICAL TRIAL
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
